Clinical Trial: Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07680946) titled 'Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia' on June 26.

Brief Summary: The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by positive and negative syndrome scale (PANSS) total score in participants with schizophrenia.

Study Start Date: July 06

Study Type: INTERVENTIONAL

Condition: Schizophrenia

Intervention: DRUG: Ublituximab

Administered as an IV infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: TG Therapeutics, Inc.

Disclaimer: Curated by HT Syndication....